Literature DB >> 34951963

RNA circles with minimized immunogenicity as potent PKR inhibitors.

Chu-Xiao Liu1, Si-Kun Guo1, Fang Nan2, Yi-Feng Xu1, Li Yang3, Ling-Ling Chen4.   

Abstract

Exon back-splicing-generated circular RNAs, as a group, can suppress double-stranded RNA (dsRNA)-activated protein kinase R (PKR) in cells. We have sought to synthesize immunogenicity-free, short dsRNA-containing RNA circles as PKR inhibitors. Here, we report that RNA circles synthesized by permuted self-splicing thymidylate synthase (td) introns from T4 bacteriophage or by Anabaena pre-tRNA group I intron could induce an immune response. Autocatalytic splicing introduces ∼74 nt td or ∼186 nt Anabaena extraneous fragments that can distort the folding status of original circular RNAs or form structures themselves to provoke innate immune responses. In contrast, synthesized RNA circles produced by T4 RNA ligase without extraneous fragments exhibit minimized immunogenicity. Importantly, directly ligated circular RNAs that form short dsRNA regions efficiently suppress PKR activation 103- to 106-fold higher than reported chemical compounds C16 and 2-AP, highlighting the future use of circular RNAs as potent inhibitors for diseases related to PKR overreaction.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PKR; PKR inhibitor; T4 RNA ligase; circular RNA; circular RNA structure; dsRNA; group I intron; immune response; permuted Anabaena pre-tRNA group I intron; phage T4 thymidylate synthase gene

Mesh:

Substances:

Year:  2021        PMID: 34951963     DOI: 10.1016/j.molcel.2021.11.019

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  8 in total

1.  Circular RNA migration in agarose gel electrophoresis.

Authors:  Brian T Abe; R Alexander Wesselhoeft; Robert Chen; Daniel G Anderson; Howard Y Chang
Journal:  Mol Cell       Date:  2022-03-30       Impact factor: 19.328

2.  The HOPE for Pandora's Box of artificial circular RNA immunogenicity.

Authors:  Faryal Mehwish Awan
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-13       Impact factor: 10.183

3.  Circular RNA vaccines against SARS-CoV-2 and emerging variants.

Authors:  Liang Qu; Zongyi Yi; Yong Shen; Liangru Lin; Feng Chen; Yiyuan Xu; Zeguang Wu; Huixian Tang; Xiaoxue Zhang; Feng Tian; Chunhui Wang; Xia Xiao; Xiaojing Dong; Li Guo; Shuaiyao Lu; Chengyun Yang; Cong Tang; Yun Yang; Wenhai Yu; Junbin Wang; Yanan Zhou; Qing Huang; Ayijiang Yisimayi; Shuo Liu; Weijin Huang; Yunlong Cao; Youchun Wang; Zhuo Zhou; Xiaozhong Peng; Jianwei Wang; Xiaoliang Sunney Xie; Wensheng Wei
Journal:  Cell       Date:  2022-04-01       Impact factor: 66.850

Review 4.  New insights on circular RNAs and their potential applications as biomarkers, therapeutic agents, and preventive vaccines in viral infections: with a glance at SARS-CoV-2.

Authors:  Nasim Rahmani-Kukia; Ardeshir Abbasi
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-14       Impact factor: 10.183

Review 5.  RNA-based therapeutics: an overview and prospectus.

Authors:  Yiran Zhu; Liyuan Zhu; Xian Wang; Hongchuan Jin
Journal:  Cell Death Dis       Date:  2022-07-23       Impact factor: 9.685

Review 6.  Promising Roles of Circular RNAs as Biomarkers and Targets for Potential Diagnosis and Therapy of Tuberculosis.

Authors:  Yifan Huang; Ying Li; Wensen Lin; Shuhao Fan; Haorong Chen; Jiaojiao Xia; Jiang Pi; Jun-Fa Xu
Journal:  Biomolecules       Date:  2022-09-04

Review 7.  Function and Clinical Significance of Circular RNAs in Thyroid Cancer.

Authors:  Xuelin Yao; Qiu Zhang
Journal:  Front Mol Biosci       Date:  2022-07-22

Review 8.  Phase separation in immune signalling.

Authors:  Qian Xiao; Ceara K McAtee; Xiaolei Su
Journal:  Nat Rev Immunol       Date:  2021-07-06       Impact factor: 53.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.